<DOC>
	<DOC>NCT00320060</DOC>
	<brief_summary>The primary objective of the study is to evaluate the safety and tolerability of Pyridorin (pyridoxamine dihydrochloride) 50 mg given orally twice daily in patients with diabetic kidney disease.</brief_summary>
	<brief_title>Effect of Pyridorin in Patients With Diabetic Nephropathy</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Diabetic Nephropathies</mesh_term>
	<mesh_term>Pyridoxamine</mesh_term>
	<criteria>Males and Females (nonpregnant and nonlactating) between 18 and 70 years of age with type 1 or type 2 diabetes Sitting blood pressure of &lt;=170/100 mm Hg at weeks 2 and 1 Hemoglobin A1C &lt;=12% at week 2 Patients with diagnosis of diabetic nephropathy as defined by 1. Serum Creatinine &lt;=2.0 mg/dL at weeks 2 and 1 2. Urinary albumin excretion &gt;=300 mg/24 hours at week 2 3. Diagnosis of diabetic retinopathy Creatinine clearance &gt;=40 mL/min at weeks 2 and 1 Voluntary written consent to participate in this study History of allergic or adverse response to any B vitamin History of major cardiovascular or cerebrovascular events History of cancer except adequately treated basal or squamous cell carcinoma of the skin History of diabetic ketoacidosis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2006</verification_date>
	<keyword>Diabetic nephropathy</keyword>
	<keyword>Advanced Glycation Endproduct Inhibitor</keyword>
	<keyword>Pyridorin</keyword>
	<keyword>Pyridoxamine</keyword>
</DOC>